ATE460180T1 - Prodrugs und verfahren zu deren herstellung - Google Patents
Prodrugs und verfahren zu deren herstellungInfo
- Publication number
- ATE460180T1 ATE460180T1 AT99967462T AT99967462T ATE460180T1 AT E460180 T1 ATE460180 T1 AT E460180T1 AT 99967462 T AT99967462 T AT 99967462T AT 99967462 T AT99967462 T AT 99967462T AT E460180 T1 ATE460180 T1 AT E460180T1
- Authority
- AT
- Austria
- Prior art keywords
- leu
- prodrugs
- prodrug
- therapeutic agent
- ssala
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 10
- 229940002612 prodrug Drugs 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 4
- 229940124597 therapeutic agent Drugs 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 230000001988 toxicity Effects 0.000 abstract 3
- 231100000419 toxicity Toxicity 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11179398P | 1998-12-11 | 1998-12-11 | |
| US11931299P | 1999-02-08 | 1999-02-08 | |
| PCT/US1999/030393 WO2000033888A2 (en) | 1998-12-11 | 1999-12-10 | Prodrug compounds and process for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE460180T1 true ATE460180T1 (de) | 2010-03-15 |
Family
ID=26809248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99967462T ATE460180T1 (de) | 1998-12-11 | 1999-12-10 | Prodrugs und verfahren zu deren herstellung |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1144011B1 (de) |
| JP (1) | JP2003518000A (de) |
| AT (1) | ATE460180T1 (de) |
| AU (1) | AU773420B2 (de) |
| CA (1) | CA2354766A1 (de) |
| CY (1) | CY1111094T1 (de) |
| DE (1) | DE69942128D1 (de) |
| DK (1) | DK1144011T3 (de) |
| ES (1) | ES2342637T3 (de) |
| IL (2) | IL143666A0 (de) |
| NZ (1) | NZ512171A (de) |
| PT (1) | PT1144011E (de) |
| WO (1) | WO2000033888A2 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2172303T3 (es) | 1998-01-23 | 2002-09-16 | Newbiotics Inc | Agentes terapeuticos obtenidos por catalisis enzimatica. |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| BR9912053A (pt) | 1998-07-13 | 2001-04-03 | Univ Texas | Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
| US6613879B1 (en) | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
| MXPA01011502A (es) | 1999-05-14 | 2003-08-20 | Boehringer Ingelheim Pharma | Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas. |
| JP2003527317A (ja) * | 1999-07-22 | 2003-09-16 | ニューバイオティックス インコーポレイテッド | 酵素触媒抗感染性治療剤 |
| IL147749A0 (en) * | 1999-07-22 | 2002-08-14 | Newbiotics Inc | Methods for treating therapy-resistant tumors |
| US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
| DE10018617A1 (de) * | 2000-01-13 | 2001-10-31 | Joerg G Moser | Cyclodextrin-Dimere mit Peptid-Spacerstrukturen zur Entgiftung von pharmazeutischen Wirkstoffen hohen Nebenwirkungspotentials |
| AU4583601A (en) | 2000-03-15 | 2001-09-24 | Du Pont Pharm Co | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| AU2001266853B2 (en) | 2000-06-14 | 2005-02-17 | Medarex, Inc. | Prodrug compounds with an oligopeptide having an isoleucine residue |
| EP1294405A2 (de) * | 2000-06-14 | 2003-03-26 | Corixa Corporation | Durch thimet oligopeptidase spaltbare prodrugs |
| AU2001275525B2 (en) | 2000-06-14 | 2007-04-26 | Medarex, Inc. | Tripeptide prodrug compounds |
| WO2002015700A1 (en) * | 2000-08-24 | 2002-02-28 | Coulter Pharmaceutical, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
| SK5122003A3 (en) * | 2000-10-27 | 2003-12-02 | Aventis Pharma Sa | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
| CA2428971A1 (en) * | 2000-11-14 | 2003-05-01 | New River Pharmaceuticals Inc. | Conjugates of a therapeutic agent and a peptide carrier |
| US20040097586A1 (en) * | 2001-01-30 | 2004-05-20 | Andre Trouet | Anti-tumor compounds |
| KR20030033007A (ko) | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
| ES2364452T3 (es) * | 2001-06-11 | 2011-09-02 | Medarex, Inc. | Método para diseñar compuestos profármacos activados por cd10. |
| FR2825928B1 (fr) * | 2001-06-18 | 2004-04-02 | Ecole Norm Superieure Cachan | Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine |
| AU2003233238A1 (en) * | 2002-05-10 | 2003-11-11 | Boehringer Ingelheim Pharma Gmbh And Co Kg | Fap-activated anti-tumor prodrugs |
| US7378386B2 (en) | 2002-07-15 | 2008-05-27 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives |
| US7678386B2 (en) | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
| US7511124B2 (en) | 2002-07-15 | 2009-03-31 | Board Of Regents, The University Of Texas System | Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents |
| US7384909B2 (en) | 2002-07-15 | 2008-06-10 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents |
| US7879801B2 (en) * | 2002-07-15 | 2011-02-01 | Board Of Regents, The University Of Texas System | Compositions comprising cell-impermeant duramycin derivatives |
| US7053051B2 (en) | 2003-10-28 | 2006-05-30 | Medtronic, Inc. | Methods of preparing crosslinked materials and bioprosthetic devices |
| EP3075247B1 (de) | 2004-02-02 | 2022-10-12 | BioSight Ltd. | Konjugate für die krebstherapie und -diagnose |
| BRPI0510909A2 (pt) | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
| WO2006095345A2 (en) | 2005-03-08 | 2006-09-14 | Ramot At Tel-Aviv University Ltd. | Targeted drug-carrying bacteriophages |
| EP1993608A1 (de) * | 2006-03-10 | 2008-11-26 | Diatos | Über einen enzym-spaltbaren linker an einen antikörper konjugierte arzneimittel gegen krebs |
| SG177168A1 (en) | 2006-12-01 | 2012-01-30 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | 梅達雷克斯有限責任公司 | 化學鏈接劑與可裂解基質以及其之綴合物 |
| JP2010519310A (ja) | 2007-02-21 | 2010-06-03 | メダレックス インコーポレイテッド | 単一のアミノ酸を有する化学リンカーおよびその複合体 |
| EP1977765A1 (de) * | 2007-04-03 | 2008-10-08 | Diatos | Peptid-Prodrugs |
| EP2833905B1 (de) | 2012-04-04 | 2018-05-02 | Halozyme, Inc. | Kombinationbehnadlung von hyaluronidase und einem tumor-gerichteten taxane |
| CN104884091B (zh) | 2012-12-28 | 2021-07-20 | 科比欧尔斯公司 | 最低毒性的药物前体 |
| US10450343B2 (en) | 2013-03-21 | 2019-10-22 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| HUE034308T2 (en) | 2013-03-21 | 2018-02-28 | Sanofi Aventis Deutschland | Preparation of hydantoin-containing peptide products |
| WO2014197816A1 (en) * | 2013-06-06 | 2014-12-11 | Massachusetts Institute Of Technology | Stimulus responsive nanocomplexes and methods of use thereof |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| EP3383883A4 (de) | 2015-12-03 | 2019-07-24 | BioSight Ltd. | Salze von konjugaten zur krebstherapie |
| JP7149183B2 (ja) | 2015-12-03 | 2022-10-06 | バイオサイト リミテッド | 癌治療のためのシタラビンコンジュゲート |
| CN109021065B (zh) * | 2017-06-08 | 2021-10-01 | 复旦大学 | 一种制备海兔毒素Dolastatin10的方法 |
| AU2021405744A1 (en) | 2020-12-22 | 2023-08-03 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0037388B1 (de) * | 1980-03-31 | 1984-12-12 | Institut International De Pathologie Cellulaire Et Moleculaire | Pharmazeutische Stoffe, deren Herstellung und Präparate in denen diese enthalten sind |
| US5155210A (en) * | 1990-09-11 | 1992-10-13 | Brunswick Corporation | Methods of conjugating actinomycin d |
| JP2610792B2 (ja) * | 1993-02-26 | 1997-05-14 | 株式会社ディ・ディ・エス研究所 | 多糖誘導体および薬物担体 |
| DE69535665T2 (de) * | 1994-08-19 | 2009-04-02 | La Region Wallonne | Konjugate enthaltend ein antitumorales mittel und deren verwendung |
| AU715632B2 (en) * | 1996-09-12 | 2000-02-03 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| HRP970566A2 (en) * | 1996-10-30 | 1998-08-31 | Jones Deborah Defeo | Conjugates useful in the treatment of prostate canser |
| WO1998052966A1 (en) * | 1997-05-19 | 1998-11-26 | The Johns Hopkins University School Of Medecine | Tissue specific prodrug |
| ATE256473T1 (de) * | 1997-07-10 | 2004-01-15 | Merck & Co Inc | Konjugate welche bei der behandlung von prostatakrebs nützlich sind |
| EP1036093A1 (de) * | 1997-12-02 | 2000-09-20 | Merck & Co., Inc. | Konjugate zur verwendung in der behandlung von prostatakrebs |
-
1999
- 1999-12-10 JP JP2000586378A patent/JP2003518000A/ja active Pending
- 1999-12-10 NZ NZ512171A patent/NZ512171A/en not_active IP Right Cessation
- 1999-12-10 ES ES99967462T patent/ES2342637T3/es not_active Expired - Lifetime
- 1999-12-10 WO PCT/US1999/030393 patent/WO2000033888A2/en not_active Ceased
- 1999-12-10 DK DK99967462.5T patent/DK1144011T3/da active
- 1999-12-10 AU AU23733/00A patent/AU773420B2/en not_active Ceased
- 1999-12-10 AT AT99967462T patent/ATE460180T1/de active
- 1999-12-10 IL IL14366699A patent/IL143666A0/xx active IP Right Grant
- 1999-12-10 EP EP99967462A patent/EP1144011B1/de not_active Expired - Lifetime
- 1999-12-10 CA CA002354766A patent/CA2354766A1/en not_active Abandoned
- 1999-12-10 DE DE69942128T patent/DE69942128D1/de not_active Expired - Lifetime
- 1999-12-10 PT PT99967462T patent/PT1144011E/pt unknown
-
2001
- 2001-06-10 IL IL143666A patent/IL143666A/en not_active IP Right Cessation
-
2010
- 2010-06-10 CY CY20101100510T patent/CY1111094T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000033888A9 (en) | 2001-05-10 |
| DE69942128D1 (de) | 2010-04-22 |
| AU2373300A (en) | 2000-06-26 |
| WO2000033888A3 (en) | 2001-11-08 |
| JP2003518000A (ja) | 2003-06-03 |
| DK1144011T3 (da) | 2010-07-05 |
| WO2000033888A2 (en) | 2000-06-15 |
| NZ512171A (en) | 2004-07-30 |
| IL143666A (en) | 2009-02-11 |
| EP1144011A2 (de) | 2001-10-17 |
| CY1111094T1 (el) | 2015-10-07 |
| PT1144011E (pt) | 2010-06-16 |
| IL143666A0 (en) | 2002-04-21 |
| CA2354766A1 (en) | 2000-06-15 |
| EP1144011B1 (de) | 2010-03-10 |
| AU773420B2 (en) | 2004-05-27 |
| HK1039272A1 (en) | 2002-04-19 |
| ES2342637T3 (es) | 2010-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69942128D1 (de) | Prodrugs und verfahren zu deren herstellung | |
| US7442386B2 (en) | Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies | |
| DE69833798T2 (de) | Trialkyl-blockierung-vereinfachte polymerische medikamentenvorstufen von aminogruppen enthaltenden bioaktiven substanzen | |
| US5760072A (en) | Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy | |
| EP3791897A1 (de) | Hsp9-inhibitor-wirkstoff-konjugate | |
| EP3277660B1 (de) | Wasserlösliche l-dopa-ester | |
| CA2478066A1 (en) | Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting | |
| AU2002324723A1 (en) | Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies | |
| WO2004019993A1 (en) | Self-immolative dendrimers releasing many active moieties upon a single activating event | |
| JP2016538281A (ja) | 血液脳関門を通過するタンパク質ホスファターゼ阻害剤 | |
| LV12886B (en) | Acyl pseudodipeptides which carry a functionalised auxiliary arm | |
| JP2003528851A (ja) | セラミド誘導体と使用方法 | |
| WO2014013995A1 (ja) | KRAS遺伝子発現抑制RNAi医薬組成物 | |
| JP2013544289A (ja) | ６−シクロヘキシル−１−ヒドロキシ−４−メチルピリジン−２（１ｈ）−オンのプロドラッグおよびその誘導体 | |
| DE69917281T2 (de) | Coumarin und damit verwandte aromatische polymere prodrugs | |
| CN104262241B (zh) | 5-氨基酮戊酸与3-羟基吡啶-4-酮的缀合物及其制备法和用途 | |
| JPWO2015186770A1 (ja) | ＣＫＡＰ５遺伝子発現抑制ＲＮＡｉ医薬組成物 | |
| EP4640669A1 (de) | Cycloalkanbasierte lipidverbindung zur abgabe von nukleinsäuren und lipidnanopartikel damit | |
| EP3641832B1 (de) | Nukleinsäure-nanokapseln zur wirkstofffreisetzung und gezielte genausschaltung | |
| JP2024511438A (ja) | 細胞への標的全身送達のための組成物および方法 | |
| CN1235594A (zh) | 用于亲水分子脂质化的方法和组合物 | |
| CN103788165B (zh) | 阿糖胞苷胆酸结合物及其制备方法和用途 | |
| JP6774965B2 (ja) | カチオン性脂質としての化合物 | |
| CN117750948A (zh) | 用于靶向全身性递送至细胞的组合物和方法 | |
| JP2019535824A (ja) | 胃腸ポリープの処置のための組成物及び方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1144011 Country of ref document: EP |